<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646891</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-041</org_study_id>
    <nct_id>NCT02646891</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants</brief_title>
  <official_title>Phase I/II Double-blind, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study of the Safety, and Immunogenicity of the Trivalent P2-VP8 Subunit Rotavirus Vaccine in Healthy South African Adults, Toddlers and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is is a study of a parenteral trivalent rotavirus vaccine (P2-VP8 subunit rotavirus
      vaccine). The study will examine the safety and immunogenicity of three dose levels of this
      vaccine in healthy South African adults, toddlers and infants. Progression from one dose
      level to another and to the next age group population will be based on the assessment of
      safety information from the lowest dose and older age group.

      The primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and
      well-tolerated. The primary immunogenicity hypothesis is that the trivalent P2-VP8 subunit
      rotavirus vaccine is immunogenic in infant participants and will induce an immune response to
      at least 2 of the 3 strains in 60% or more of participants in at least one of the study
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>from day 0 to day 28 post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>from day 0 to day 28 post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with vaccine related reactogenicity events</measure>
    <time_frame>Day 0 to day 7 post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with anti-P2VP8 IgG sero responses by Elisa</measure>
    <time_frame>day 0 to day 28 post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with anti-P2VP8 IgA seroresponses by Elisa</measure>
    <time_frame>Day 0 to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with neutralizing antibody responses</measure>
    <time_frame>day 0 to day 28 post vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">609</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A1 - Adult TV P2VP8 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A 1 - Adults receiving low dose Trivalent P2VP8 (30 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1 - Adult Placebo (30mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group A 1 - Adults receiving Placebo (for low dose 30 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 - Adult TV P2VP8 90 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A2 - Adults receiving higher dose Trivalent P2VP8 (90 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 - Adult Placebo (90 mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group A2 - Adults receiving Placebo (for higher dose 90 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 - Toddler TV P2VP8 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B1 - Toddlers receiving low dose Trivalent P2VP8 (30 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 - Toddler Placebo (30mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B1 - Toddlers receiving Placebo (for low dose 30 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 - Toddler TV P2VP8 90 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B2 - Toddlers receiving low dose Trivalent P2VP8 (90 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 - Toddler Placebo (180mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B2 - Toddlers receiving Placebo (for low dose 90 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 - Infant TV P2VP8 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C1 - Infants receiving Trivalent P2VP8 (15 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 - Infant Placebo (15 mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C1 - Infants receiving Placebo (for 15 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 - Infant TV P2VP8 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C2 - Infants receivingTrivalent P2VP8 (30 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 - Infant Placebo (30mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C2 - Infants receiving Placebo (for 30 mcg group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 - Infant TV P2VP8 90 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C3 - Infants receiving Trivalent P2VP8 (90 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 - Infant Placebo (90 mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C3 - Infants receiving Placebo (for 90 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Infant TV P2VP8 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D - Expanded group of infants receiving Trivalent P2VP8 (15 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Infant TV P2VP8 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D - Expanded group of infants receiving Trivalent P2VP8 (30 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Infant TV P2VP8 90 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D - Expanded group of infants receiving Trivalent P2VP8 (90 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Infant Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group D - Expanded group of infants receiving Placebo ( for 15 mcg, 30 mcg and 90 mcg groups)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 15 mcg</intervention_name>
    <arm_group_label>C1 - Infant TV P2VP8 15 mcg</arm_group_label>
    <arm_group_label>D - Infant TV P2VP8 15 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 30 mcg</intervention_name>
    <arm_group_label>A1 - Adult TV P2VP8 30 mcg</arm_group_label>
    <arm_group_label>B1 - Toddler TV P2VP8 30 mcg</arm_group_label>
    <arm_group_label>C2 - Infant TV P2VP8 30 mcg</arm_group_label>
    <arm_group_label>D - Infant TV P2VP8 30 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>A1 - Adult Placebo (30mcg)</arm_group_label>
    <arm_group_label>A2 - Adult Placebo (90 mcg)</arm_group_label>
    <arm_group_label>B1 - Toddler Placebo (30mcg)</arm_group_label>
    <arm_group_label>B2 - Toddler Placebo (180mcg)</arm_group_label>
    <arm_group_label>C1 - Infant Placebo (15 mcg)</arm_group_label>
    <arm_group_label>C2 - Infant Placebo (30mcg)</arm_group_label>
    <arm_group_label>C3 - Infant Placebo (90 mcg)</arm_group_label>
    <arm_group_label>D - Infant Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 90 mcg</intervention_name>
    <arm_group_label>A2 - Adult TV P2VP8 90 mcg</arm_group_label>
    <arm_group_label>B2 - Toddler TV P2VP8 90 mcg</arm_group_label>
    <arm_group_label>C3 - Infant TV P2VP8 90 mcg</arm_group_label>
    <arm_group_label>D - Infant TV P2VP8 90 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults (≥18 and ≤45 years), toddlers (≥2 and ≤3 years), and infants (≥6 and ≤8
             weeks)

          -  Participants will remain in the area during the study

          -  Females of childbearing potential must not be pregnant or breastfeeding, and willing
             to use adequate method of contraception during the trial.

        Exclusion Criteria:

          -  Presence of fever or other acute illness

          -  concurrent participation in another clinical trial

          -  Presence of malnutrition or other systemic disorder.

          -  Infants with history of premature birth (&lt;37 wk gestational age)

          -  History of congenital abdominal disorders or surgery

          -  Suspected or known impairment of immune function

          -  Infants who have received rotavirus vaccine in the past

          -  Known sensitivity to any components of the vaccine

          -  History of anaphylactic reaction

          -  Major congenital or genetic defect

          -  Unwillingness to follow study schedule

          -  Receipt of immunoglobulin therapy or blood products in last 6 months

          -  History of chronic immunosuppressive medications (with the exception of inhaled or
             topical steroids)

          -  Any medical condition that, in the judgement of the investigator, would interfere with
             the protocol, or would interfere with participant's ability to adhere to the study
             protocol.

          -  Clinically significant screening laboratory value

          -  HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Groom, MBBCh</last_name>
    <role>Study Chair</role>
    <affiliation>Chris Hani Baragwanath Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit (RMPRU)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandukani Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit (FAM-CRU) Stellenbosch Univ</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotavirus Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

